Rebel Medicine

Executive Summary

Rebel Medicine is a San Francisco-based biotech focused on developing non-opioid solutions for acute pain, addressing the critical need for safer alternatives amid the opioid crisis. Founded in 2020, the company leverages proprietary drug delivery technologies to create long-acting local anesthetics. Its lead candidate, Alevatrix™, is an injectable gel designed to provide 72–96 hours of post-operative pain relief, potentially reducing opioid dependence and improving recovery. Currently in Phase 2 clinical development, Alevatrix targets a large market in surgical pain management. While still early-stage, Rebel Medicine's platform has the potential to disrupt standard care with a non-addictive, prolonged-duration anesthetic. Key risks include clinical trial execution, regulatory pathway, and competition from existing local anesthetics and other non-opioid contenders. The company's progress in Phase 2 will be critical to validating its technology and attracting partnerships or funding for late-stage development.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Trial Results for Alevatrix55% success
• TBDStrategic Partnership or Licensing Deal50% success
• Q4 2026Series B or C Financing Round70% success